Why we need easy access to all data from all clinical trials and how to accomplish it
暂无分享,去创建一个
[1] Mark Walport,et al. Sharing research data to improve public health , 2011, The Lancet.
[2] Sally Hopewell,et al. Publication bias in clinical trials due to statistical significance or direction of trial results. , 2009, The Cochrane database of systematic reviews.
[3] A. Wertheimer,et al. Why Patients Continue to Participate in Clinical Research , 2008 .
[4] L. Stalley,et al. The Influence of the Pharmaceutical Industry , 2004 .
[5] Ray Moynihan. Overdo$ed America: The Broken Promise of American Medicine , 2004, BMJ : British Medical Journal.
[6] M. Egger,et al. COX 2 inhibitors, traditional NSAIDs, and the heart , 2005, BMJ : British Medical Journal.
[7] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.
[8] Silvio Garattini,et al. Efficacy, safety, and cost of new anticancer drugs , 2002, BMJ : British Medical Journal.
[9] Matthew J. Thompson,et al. Ensuring safe and effective drugs: who can do what it takes? , 2011, BMJ : British Medical Journal.
[10] Lethia Collins Rn Msn Cnor Cfnp. Overdo$ed America: The Broken Promise of American Medicine , 2006 .
[11] A. Hrõbjartsson,et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.
[12] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[13] C. Grady,et al. Why patients continue to participate in clinical research. , 2008, Archives of internal medicine.
[14] E. Topol,et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.
[15] Douglas G Altman,et al. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols , 2008, BMJ : British Medical Journal.
[16] H. Wulff,et al. Rational diagnosis and treatment. , 1986, The Journal of medicine and philosophy.
[17] N. Hadler. Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer , 2007 .
[18] R. Matthews. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2008, Journal of Nuclear Medicine.
[19] Eric J Topol,et al. Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.
[20] D. Cohen. Rosiglitazone: what went wrong? , 2010, BMJ : British Medical Journal.
[21] D. Eyding,et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials , 2010, BMJ : British Medical Journal.
[22] J. Avorn. Dangerous deception--hiding the evidence of adverse drug effects. , 2006, The New England journal of medicine.
[23] D. Cohen. Complications: tracking down the data on oseltamivir , 2009, BMJ : British Medical Journal.
[24] R. DeRubeis,et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.
[25] D. Carr. Wellcome Trust Policy on Data Management and Sharing , 2011 .
[26] Merrill Goozner,et al. The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .
[27] Lise,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[28] A. Andreasen. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health , 2005 .
[29] W. Fitzgerald. Corporate Crime in the Pharmaceutical industry , 1984 .
[30] Richard M. Smith,et al. Big publishers cut access to journals in poor countries , 2011, The Lancet.
[31] D. Healy. Did regulators fail over selective serotonin reuptake inhibitors? , 2006, BMJ : British Medical Journal.
[32] G. Sweeney,et al. Global corruption report , 2011 .
[33] Lisa Bero,et al. Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others , 2007, PLoS medicine.
[34] P. Jesilow. Prescription for profit , 1993 .
[35] J Savulescu,et al. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability , 1996, BMJ.
[36] Alex Berenson,et al. Evidence in Vioxx suits shows intervention by Merck officials. , 2005, The New York times on the Web.
[37] F. Mosteller,et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.
[38] J. Jureidini,et al. Clinical trials and drug promotion: Selective reporting of study 329 , 2008 .
[39] H. Chaiklin. On the Take: How Medicine??s Complicity With Big Business Can Endanger Your Health , 2006 .
[40] P. Gøtzsche,et al. Opening up data at the European Medicines Agency , 2011, BMJ : British Medical Journal.
[41] Trish Groves. Managing UK research data for future use , 2009, BMJ : British Medical Journal.
[42] B. Caldwell,et al. Risk of Cardiovascular Events and Celecoxib: a Systematic Review and Meta-Analysis , 2006 .
[43] P. Gøtzsche,et al. Rational Diagnosis and Treatment: Evidence-Based Clinical Decision-Making , 2000 .
[44] P. Glasziou,et al. Avoidable waste in the production and reporting of research evidence , 2009, The Lancet.
[45] L. Dopson,et al. What Went Wrong? , 2007, Wollstonecraft.
[46] Peter Rost,et al. The Whistleblower: Confessions of a Healthcare Hitman , 2006 .
[47] E. Topol,et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.
[48] John Braithwaite,et al. Corporate Crime in the Pharmaceutical Industry , 1984 .
[49] S. Goldbeck-Wood. Denmark takes a lead on research ethics , 1998, BMJ.
[50] Kay Dickersin,et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. , 2009, The New England journal of medicine.
[51] Jeanne Lenzer,et al. FDA is incapable of protecting US “against another Vioxx” , 2004, BMJ : British Medical Journal.
[52] D. Altman,et al. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers , 2010, BMJ : British Medical Journal.
[53] L. Marsa. Prescription for Profits : How the Pharmaceutical Industry Bankrolled the Unholy Marriage Between Science and Business , 1997 .
[54] Jeffrey M Drazen,et al. Expression of concern reaffirmed. , 2006, The New England journal of medicine.
[55] S. Goodman,et al. A Systematic Examination of the Citation of Prior Research in Reports of Randomized, Controlled Trials , 2011, Annals of Internal Medicine.
[56] R. Temple,et al. Drug-review deadlines and safety problems. , 2008, The New England journal of medicine.
[57] T. Furukawa. All clinical trials must be reported in detail and made publicly available , 2004, BMJ : British Medical Journal.
[58] Other. Communication from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions: Annual Policy Strategy for 2008 , 2007 .
[59] D. Rennie,et al. Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.
[60] P. Gøtzsche,et al. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. , 1999, JAMA.
[61] S. Shoor,et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.
[62] N. Scott,et al. Outcome reporting bias and individual patient data meta-analysis: a case study in surgery , 2001 .
[63] The truth about drug companies: how they deceive us and what to do about it , 2006 .
[64] Nicki Panoskaltsis,et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.
[65] Brian Hutton,et al. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? , 2005, Clinical trials.
[66] D. Safer. DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS , 2002, The Journal of nervous and mental disease.
[67] R. Moynihan,et al. Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning Us All into Patients , 2005 .
[68] J. Kassirer. On the Take , 2005 .
[69] Douglas G Altman,et al. Comparison of protocols and registry entries to published reports for randomised controlled trials. , 2011, The Cochrane database of systematic reviews.
[70] J. Abramson. Overdosed America: The Broken Promise of American Medicine , 2004 .
[71] T. Cymet,et al. The Truth about Drug Companies: How They Deceive Us and What to Do about It , 2006 .
[72] B. Wieseler,et al. Finding studies on reboxetine: a tale of hide and seek , 2010, BMJ : British Medical Journal.
[73] R. Rosenthal,et al. Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.
[74] A. Hrõbjartsson,et al. [Constraints on publication rights in industry-initiated clinical trials--secondary publication]. , 2006, Ugeskrift for laeger.
[75] A. Skene,et al. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. , 1993, International journal of cardiology.
[76] D. Altman,et al. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.
[77] B. Beermann,et al. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.
[78] Peter Jüni,et al. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? , 2002, BMJ : British Medical Journal.
[79] Jerry Avorn,et al. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs , 2004 .
[80] G. K. Chambers,et al. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. , 2001, JAMA.
[81] H. Brody,et al. Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry , 2006 .
[82] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[83] Geoffrey C. Bowker,et al. Promoting Access to Public Research Data for Scientific, Economic, and Social Development , 2004, Data Sci. J..
[84] Richard Beasley,et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. , 2006, Journal of the Royal Society of Medicine.
[85] M. Gordon. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412 , 2008 .
[86] Michele Harms,et al. Clinical trial registration. , 2011, Physiotherapy.
[87] G. Pc. Bias in double-blind trials. , 1990 .
[88] Ana Marusic,et al. Clinical trial registration: looking back and moving ahead , 2007, The Lancet.
[89] M. Hanefeld,et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.
[90] A. Hrõbjartsson,et al. Constraints on publication rights in industry-initiated clinical trials. , 2006, JAMA.
[91] Jeffrey M Drazen,et al. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. , 2005, The New England journal of medicine.
[92] T. Pang,et al. From Mexico to Mali: four years in the history of clinical trial registration , 2009, Journal of evidence-based medicine.
[93] J. Avorn,et al. Drug-review deadlines and safety problems. , 2008, The New England journal of medicine.
[94] M. Angell. The Truth About the Drug Companies: How They Deceive Us and What to Do About It , 2004 .
[95] C. Deangelis,et al. Ensuring integrity in industry-sponsored research: primum non nocere, revisited. , 2010, JAMA.
[96] P. Gøtzsche. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. , 1989, Controlled clinical trials.
[97] Bruce M. Psaty,et al. Minimizing bias in randomized trials: the importance of blinding. , 2010, JAMA.
[98] Karen Ekernas,et al. Facemasks and Hand Hygiene to Prevent Influenza Transmission in Households: A Cluster Randomized Trial , 2010 .
[99] G. Annas. Globalized clinical trials and informed consent. , 2009, The New England journal of medicine.
[100] L. Mcgoey,et al. If NICE was in the USA , 2009, The Lancet.
[101] S. Garattini. Confidentiality , 2003, The Lancet.
[102] J. Brophy. Selling safety--lessons from muraglitazar. , 2005, JAMA.
[103] J. Tanne. Pfizer pays record fine for off-label promotion of four drugs , 2009, BMJ : British Medical Journal.
[104] T. Chalmers,et al. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. , 1981, The New England journal of medicine.
[105] D. Graham,et al. More on advisory committee decision , 2010, BMJ : British Medical Journal.
[106] A. Vickers,et al. Empirical Study of Data Sharing by Authors Publishing in PLoS Journals , 2009, PloS one.
[107] P. Lurie,et al. Misleading data analyses in salmeterol (SMART) study , 2005, The Lancet.
[108] J. Abraham. Science, politics, and the pharmaceutical industry , 1995 .
[109] B. Lewis. What Went Wrong , 2001 .
[110] Lisa Bero,et al. Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation , 2008, PLoS medicine.
[111] Hooman Momen. Equitable access to scientific and technical information for health. , 2003, Bulletin of the World Health Organization.